← Leaderboards
Craig Walter Hendrix
Johns Hopkins University
$25,690,627
Attributed
$27,708,152
Total exposure
34
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$48,387,493 · 35
By mechanism
U19$36,715,771 · 7
P30$3,592,267 · 2
T32$2,676,898 · 1
R01$2,168,503 · 1
M01$1,662,430 · 21
R56$725,624 · 1
Top collaborators
- Kelly E. Dooley7 shared
- Jenell S Coleman4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Randall R Reed$8,439,469
- Elia J Duh$12,153,743
- Joshua T Mendell$10,907,449
- Jacques Ravel$18,661,935
- David Sidransky$59,922,938
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHiv InfectionsSamplingHuman SubjectTissuesPharmaceutical PreparationsDosePharmacokineticsDrug KineticsFutureTenofovirBloodLiquid SubstancePreventionProgramsMicrobicideRectalPharmacodynamicsCd4 Positive T LymphocytesAnti-Retroviral AgentsAntiviral AgentsPerformanceClinical TrialsDrug Screening /Evaluation
Grant awards (96)
Clinical Laboratory & Biomarker Core$341,096
P30 · FY2025 · AI · contact PI
Clinical Laboratory & Biomarker Core$384,122
P30 · FY2024 · AI · contact PI
Clinical Laboratory & Biomarker Core$487,579
P30 · FY2023 · AI · contact PI
Clinical Pharmacology Training Program$397,279
T32 · FY2023 · GM · contact PI
Phosphorylation of Drugs in Colonic Tissue$725,624
R56 · FY2022 · AI · contact PI
Clinical Laboratory & Biomarker Core$560,703
P30 · FY2022 · AI · contact PI
Clinical Pharmacology Training Program$385,532
T32 · FY2022 · GM · contact PI
Clinical Pharmacology Training Program$382,501
T32 · FY2021 · GM · contact PI
Laboratory and Biomarkers Core$374,058
P30 · FY2021 · AI · contact PI
Population Pharmacokinetic Modeling and Clinical Trial Simulation to optimize HIV Prevention in Pregnancy and Postpartum$235,276
R21 · FY2021 · HD · contact PI
Clinical Pharmacology Training Program$393,867
T32 · FY2020 · GM · contact PI
Laboratory and Biomarkers Core$335,541
P30 · FY2020 · AI · contact PI
Clinical Pharmacology Training Program$366,076
T32 · FY2019 · GM · contact PI
Laboratory and Biomarkers Core$333,886
P30 · FY2019 · AI · contact PI
Development of Rectal Enema As Microbicide (DREAM)$4,530,478
U19 · FY2018 · AI · contact PI
Clinical optimization of a tenofovir enema and adherence tracking$1,487,919
U19 · FY2018 · AI · contact PI
Project 1: Pharmacokinetics of Combination Antiretroviral Intravaginal Rings$797,832
U19 · FY2018 · AI · contact PI
Laboratory and Biomarkers Core$365,016
P30 · FY2018 · AI · contact PI
Clinical Pharmacology Training Program$354,563
T32 · FY2018 · GM · contact PI
Development of Rectal Enema As Microbicide (DREAM)$4,573,711
U19 · FY2017 · AI · contact PI
Clinical optimization of a tenofovir enema and adherence tracking$1,325,694
U19 · FY2017 · AI · contact PI
Project 1: Pharmacokinetics of Combination Antiretroviral Intravaginal Rings$875,428
U19 · FY2017 · AI · contact PI
The effect of Depo-Provera on HIV susceptibility, immune activation, and PrEP PK$438,858
R01 · FY2017 · AI · contact PI
Laboratory and Biomarkers Core$410,266
P30 · FY2017 · AI · contact PI
Clinical Pharmacology Training Program$132,473
T32 · FY2017 · GM · contact PI
Development of Rectal Enema As Microbicide (DREAM)$4,612,049
U19 · FY2016 · AI · contact PI
Clinical optimization of a tenofovir enema and adherence tracking$972,143
U19 · FY2016 · AI · contact PI
Pre-Phase I Evaluations$742,671
U19 · FY2016 · AI · contact PI
Project 1: Pharmacokinetics of Combination Antiretroviral Intravaginal Rings$662,716
U19 · FY2016 · AI · contact PI
The effect of Depo-Provera on HIV susceptibility, immune activation, and PrEP PK$438,858
R01 · FY2016 · AI · contact PI
Clinical Pharmacology Training Program$264,607
T32 · FY2016 · GM · contact PI
Development of Rectal Enema As Microbicide (DREAM)$3,392,437
U19 · FY2015 · AI · contact PI
Clinical optimization of a tenofovir enema and adherence tracking$897,929
U19 · FY2015 · AI · contact PI
Pre-Phase I Evaluations$671,733
U19 · FY2015 · AI · contact PI
Project 1: Pharmacokinetics of Combination Antiretroviral Intravaginal Rings$557,961
U19 · FY2015 · AI · contact PI
The effect of Depo-Provera on HIV susceptibility, immune activation, and PrEP PK$438,858
R01 · FY2015 · AI · contact PI
Development of Rectal Enema As Microbicide (DREAM)$3,570,666
U19 · FY2014 · AI · contact PI
Clinical optimization of a tenofovir enema and adherence tracking$1,025,187
U19 · FY2014 · AI · contact PI
Pre-Phase I Evaluations$737,182
U19 · FY2014 · AI · contact PI
Project 1: Pharmacokinetics of Combination Antiretroviral Intravaginal Rings$584,012
U19 · FY2014 · AI · contact PI
The effect of Depo-Provera on HIV susceptibility, immune activation, and PrEP PK$438,858
R01 · FY2014 · AI · contact PI
Exploratory Pharmcokinetics of UC781 & Tenofovir Vaginal Microbicide Gel V Film$374,772
U19 · FY2014 · AI · contact PI
Pre-Phase I Evaluations$982,834
U19 · FY2013 · AI · contact PI
The effect of Depo-Provera on HIV susceptibility, immune activation, and PrEP PK$413,071
R01 · FY2013 · AI · contact PI
Exploratory Pharmcokinetics of UC781 & Tenofovir Vaginal Microbicide Gel V Film$335,404
U19 · FY2013 · AI · contact PI
Pre-Phase I Evaluations$575,586
U19 · FY2012 · AI · contact PI
Exploratory Pharmcokinetics of UC781 & Tenofovir Vaginal Microbicide Gel V Film$328,281
U19 · FY2012 · AI · contact PI
Exploratory Pharmcokinetics of UC781 & Tenofovir Vaginal Microbicide Gel V Film$427,682
U19 · FY2011 · AI · contact PI
Exploratory Pharmcokinetics of UC781 & Tenofovir Vaginal Microbicide Gel V Film$335,386
U19 · FY2010 · AI · contact PI
Phase I rectally-formulated rectal microbicide$582,849
U19 · FY2009 · AI · contact PI
METHADONE QD WITH FOSAMPRENAVIR$159,988
M01 · FY2007 · RR · contact PI
A POTENTIAL RECTAL MICROBICIDE VEHICLE AND SEMEN SURROGATE$35,314
M01 · FY2007 · RR · contact PI
INTERACTION BETWEEN AMD 11070 AND SUSTRATES OF CYP3A4 AND 2D6 ENZYMES$13,914
M01 · FY2007 · RR · contact PI
P5 - Effect of Rectal Preparatory Enemas on Microbicide Distribution, Tox$755,229
U19 · FY2006 · AI · contact PI
METHADONE QD WITH FOSAMPRENAVIR$282,114
M01 · FY2006 · RR · contact PI
A POTENTIAL RECTAL MICROBICIDE VEHICLE AND SEMEN SURROGATE$28,475
M01 · FY2006 · RR · contact PI
COLLECTION OF BIOLOGICAL SAMPLES FOR LAB ASSAY DEVELOPMENT$274
M01 · FY2006 · RR · contact PI
SAMPLING FREQUENCY LIMITATIONS OF ANTIRETROVIRAL DRUGS$130,893
M01 · FY2005 · RR
A POTENTIAL RECTAL MICROBICIDE VEHICLE AND SEMEN SURROGATE$38,624
M01 · FY2005 · RR
MALE GENITAL TRACT$29,407
M01 · FY2005 · RR
COMPARE THE SPREAD AND DISTRIBUTION OF A POTENTIAL RECTAL MICROBICIDE$17,881
M01 · FY2005 · RR
COLLECTION OF BIOLOGICAL SAMPLES FOR LAB ASSAY DEVELOPMENT$8,972
M01 · FY2005 · RR
Candida Ecology in the Intensive Care Unit$793,461
M01 · FY2004 · RR
PHARMACOLOGY OF ANTIRETROVIRAL DRUGS IN GENITAL TRACT$128,814
K24 · FY2004 · AI
SAMPLING FREQUENCY LIMITATIONS OF ANTIRETROVIRAL DRUGS$94,535
M01 · FY2004 · RR
COMPARE THE SPREAD AND DISTRIBUTION OF A POTENTIAL RECTAL MICROBICIDE$20,962
M01 · FY2004 · RR
COLLECTION OF BIOLOGICAL SAMPLES FOR LAB ASSAY DEVELOPMENT$3,917
M01 · FY2004 · RR
Antiretroviral Semen Analysis Feasibility Study$3,699
M01 · FY2004 · RR
PHARMACOLOGY OF ANTIRETROVIRAL DRUGS IN GENITAL TRACT$124,662
K24 · FY2003 · AI
PHARMACOLOGY OF ANTIRETROVIRAL DRUGS IN GENITAL TRACT$121,818
K24 · FY2002 · AI
P24 ANTIGEN LEVELS--ANTIRETROVIRAL DRUG STUDIES$0
M01 · FY2002 · RR
ACCUTANE/ORAL CONTRACEPTIVES IN WOMEN WITH NODULAR ACNE$0
M01 · FY2002 · RR
EFAVIRENZ IN COMBO WITH RITONAVIR/SAQUINAVIR IN HIV$0
M01 · FY2002 · RR
PHARMACOKINETICS OF IV AMD 3100 IN NORMAL VOLUNTEERS$0
M01 · FY2002 · RR
S1153 ACTION WITH PROTEASE INHIBITORS AND 3TC/ZVD/D4T$0
M01 · FY2002 · RR
OCULAR ACTIVITY OF ORAL 12263W94 IN AIDS CMV RETINITIS$0
M01 · FY2002 · RR
PHARMACOKINETICS/SAFETY OF LOBUCAVIR IN SUBJECTS WITH HEPATIC IMPAIRMENT$0
M01 · FY2002 · RR
PHARMACOKINETICS AND SAFETY OF LOBUCAVIR IN SUBJECTS WITH HEPATIC IMPAIRMENT$0
M01 · FY2002 · RR
PHARMACOLOGY OF ANTIRETROVIRAL DRUGS IN GENITAL TRACT$119,056
K24 · FY2001 · AI
PHARMACOKINETICS OF IV AMD 3100 IN NORMAL VOLUNTEERS$0
M01 · FY2001 · RR
S1153 ACTION WITH PROTEASE INHIBITORS AND 3TC/ZVD/D4T$0
M01 · FY2001 · RR
P24 ANTIGEN LEVELS--ANTIRETROVIRAL DRUG STUDIES$0
M01 · FY2001 · RR
ACCUTANE/ORAL CONTRACEPTIVES IN WOMEN WITH NODULAR ACNE$0
M01 · FY2001 · RR
EFAVIRENZ IN COMBO WITH RITONAVIR/SAQUINAVIR IN HIV$0
M01 · FY2001 · RR
OCULAR ACTIVITY OF ORAL 12263W94 IN AIDS CMV RETINITIS$0
M01 · FY2001 · RR
PHARMACOKINETICS/SAFETY OF LOBUCAVIR IN SUBJECTS WITH HEPATIC IMPAIRMENT$0
M01 · FY2001 · RR
PHARMACOKINETICS AND SAFETY OF LOBUCAVIR IN SUBJECTS WITH HEPATIC IMPAIRMENT$0
M01 · FY2001 · RR
PHARMACOLOGY OF ANTIRETROVIRAL DRUGS IN GENITAL TRACT$116,374
K24 · FY2000 · AI
PHARMACOKINETICS/SAFETY OF LOBUCAVIR IN SUBJECTS WITH HEPATIC IMPAIRMENT$0
M01 · FY2000 · RR
PHARMACOKINETICS AND SAFETY OF LOBUCAVIR IN SUBJECTS WITH HEPATIC IMPAIRMENT$0
M01 · FY2000 · RR
S1153 ACTION WITH PROTEASE INHIBITORS AND 3TC/ZVD/D4T$0
M01 · FY2000 · RR
P24 ANTIGEN LEVELS--ANTIRETROVIRAL DRUG STUDIES$0
M01 · FY2000 · RR
ACCUTANE/ORAL CONTRACEPTIVES IN WOMEN WITH NODULAR ACNE$0
M01 · FY2000 · RR
EFAVIRENZ IN COMBO WITH RITONAVIR/SAQUINAVIR IN HIV$0
M01 · FY2000 · RR
OCULAR ACTIVITY OF ORAL 12263W94 IN AIDS CMV RETINITIS$0
M01 · FY2000 · RR
PHARMACOKINETICS OF IV AMD 3100 IN NORMAL VOLUNTEERS$0
M01 · FY2000 · RR